Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

NCT07088718 · Completed

Last updated 2026-05-28

This trial is testing whether a new method using healthcare claims data can predict major heart-related events in people with type 2 diabetes.

Status Completed The study has finished.

Type Observational

Participants 44,671 people

Who can join Ages 40+ · all sexes

Timeline Started 2024-10 · est. completion 2025-07

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07088718 ↗

Description as written by the study sponsor.

Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Treatments tested

Tirzepatide Drug

New use of tirzepatide dispensing claim is used as the exposure.
Dulaglutide Drug

New use of dulaglutide dispensing claim is used as the reference.

Main thing measured	First occurence of MACE (all-cause mortailty, myocardial infarction, or death)
Sponsor	Brigham and Women's Hospital
Conditions studied	Type 2 Diabetes, Major Adverse Cardiac Events, Cardiovascular (CV) Risk
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07088718 ↗